Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afrezza in Closed-Loop T1D Therapy
NCT03234491Phase 1Completed
- Sponsor
- Yale University
- Start
- Nov 2017
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TI-Inhalation Powder B in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Yale University. Primary endpoint: PostPrandial Blood Glucose at 4 hours. Started Nov 2017; status: completed.
02
Drugs
TI-Inhalation Powder B
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03234491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03234491.